Bristol Myers Squibb (CELG-RI) FCF Margin (2009 - 2026)

Bristol Myers Squibb has disclosed FCF Margin across 18 years of filings, most recently posting 6.59% for Q1 2026.

• In Q1 2026, FCF Margin fell 853.0% year-over-year to 6.59%; the TTM figure through Mar 2026 stood at 24.56% (down 291.0% YoY), while the FY2025 annual figure was 26.65%, down 221.0% from the prior year.
• FCF Margin retreated to 6.59% in Q1 2026, from 12.83% in the prior quarter.
• Over the last five years, FCF Margin for CELG-RI reached as high as 49.02% in Q3 2025 and fell as low as 6.59% in Q1 2026.
• The 5-year median for FCF Margin is 25.95% (2022), against an average of 26.16%.
• The widest YoY moves for FCF Margin: up 1207 bps in 2025, down 2007 bps in 2025.
• A 5-year view of FCF Margin shows it stood at 25.95% in 2022, then surged by 32 bps to 34.17% in 2023, then decreased by 4 bps to 32.9% in 2024, then slumped by 61 bps to 12.83% in 2025, then sank by 49 bps to 6.59% in 2026.
• According to Business Quant data, FCF Margin over the past three periods registered 6.59%, 12.83%, and 49.02% for Q1 2026, Q4 2025, and Q3 2025 respectively.